Stockholm, Sweden, August 30, 2022; Today, the 30th of August 2022, Inify Laboratories AB, org. no. 559345-4431, held an extraordinary general meeting in Stockholm. Total 31,807,064 shares were represented at the general meeting, which corresponds to 70.3% of the total shares and votes. The meeting decided, with the required majority, on all matters in accordance with the board’s previously published proposal. Below follows a summary of the main decisions, for further details please refer to the notice that is available on the company’s website.
- Grant Thornton Sweden AB was elected as external auditing company, with Joakim Södering as auditor in charge, for the period until the end of next general meeting, Present auditors, Ernst & Young AB, were released from office.
- Remuneration to the board and auditors was decided according to the following:
- Remuneration to the chairman of the board is SEK 300.000.
- Remuneration to other members of the board, whom are not also main shareholders, is SEK 200.000.
- Remuneration to the auditors will be paid against invoicing, approved by the company.
For more information, please contact CEO Fredrik Palm () or visit www.inify.com
About Inify Laboratories AB (publ)
Inify Laboratories provides cancer diagnostics through ultra-modern laboratory services within histopathology. Fully digital, standardized and AI- supported workflow is applied to optimize quality and response times, initially for prostate cancer. The concept is scalable and extendible to other diagnosis. The company origins from ContextVision and became independent in February 2022. The company is based in Sweden and listed on Euronext Growth Oslo under the ticker INIFY.
This information is subject to the disclosure requirements pursuant to section 5–12 of the Norwegian Securities Trading Act.
Attachment
View attachment